South Korean drugmaker OliX Pharmaceuticals said on Monday that it has asked the US Food and Drug Administration for permission to test a new eye injection in people with geographic atrophy1. Geographic atrophy is the advanced form of dry age-related macular degeneration. It slowly destroys central vision and affects about 1 million Americans, according to Tech Times1.
The drug, called OLX301A, is a short piece of genetic material designed to switch off one gene that drives inflammation in the eye1. The filing, known as an IND (investigational new drug application, the request a company makes before testing a drug in US patients), clears the way for a planned 64-person trial1. No results showing that the drug protects sight exist yet.
What happened
The application puts OLX301A into the FDA’s standard 30-day review window. If the agency does not order a “clinical hold” (a stop on testing) within that time, OliX may begin enrolling US patients1.
The trial is planned as a Phase 2a study, an early test meant to look for first signs that a drug helps. It will enroll 64 patients at sites in the United States, Australia and New Zealand1. Patients will be split between injections of the drug into the eye and a sham procedure. In the sham group, patients get a needle prick without any drug injected, a standard design for eye-injection trials1. Korean reporting collected by CB Insights describes the design as multi-center and randomized (patients assigned to groups by chance), and says it will enroll people with geographic atrophy in both eyes who receive repeated injections2.
The main measure is the change in the area of the “ellipsoid zone,” a layer seen on an eye scan called optical coherence tomography. It is used as a structural sign of whether light-sensing cells are being preserved1.
The evidence so far
The scientific idea behind the drug comes from research published in the journal Cell in 2012 by a team led by Jayakrishna Ambati at the University of Kentucky1. In that work, an enzyme called DICER1 became less active in aging support cells of the retina. As a result, a type of repeated genetic material called Alu RNA built up instead of being broken down1. That buildup set off an inflammation chain reaction through a protein called MyD881. In mice, blocking MyD88 prevented the death of these retinal support cells even when Alu RNA levels stayed high1. These are animal results, and mice do not develop the human disease in the same way.
In people, the only data come from an earlier first-stage study that OliX completed before the US filing. According to Tech Times, it found no serious side effects linked to the drug and no doses that had to be limited because of harm1. Some patients showed better scores on a standard eye-chart test, but that study was not designed or large enough to detect whether the drug works1. The number of people in that study is not given in the sources.
What it does not show yet
- No proof of benefit. Neither the mouse work nor the small safety study shows that the drug slows vision loss in people1.
- A scan measure, not eyesight. The planned trial’s main measure is a layer seen on a scan, not how well patients see1. A change on a scan does not always mean a change people notice in daily life.
- No FDA decision yet. The filing starts a review. It is not an approval of the drug1.
- A setback in New Zealand. In October 2026, a New Zealand health and disability ethics committee returned OliX’s application for the New Zealand part of the trial, judging that it did not meet that country’s ethical standards and rules2. The company did not give detailed reasons. An OliX representative said regulators wanted some submitted materials improved and that the company would resubmit2. OliX had filed in New Zealand at the end of September, planning up to three sites there, and had also applied in Australia that month2.
Who is behind it
OliX was founded in 2010 and is based in Seongnam, South Korea2. It works on RNA interference, a way of switching off specific genes, and lists programs in skin scarring, hair loss, macular degeneration and liver diseases2. Investors listed by CB Insights include Weiss Asset Management, L’Oreal BOLD and IMM Investment2.
OliX raised a ₩110 billion funding round (about $71 million) in June 2026. Chief executive Dr. Sungkwon Chung said the money will pay for OLX301A through its Phase 2a program in the United States, Australia and New Zealand1. The company has worked on eye drugs for years. In 2020 it announced a manufacturing deal for a related eye program, OLX301D, aimed at scarring and abnormal blood vessels in wet macular degeneration3. The sources do not report any outside, independent funding for the new trial.
How it fits the field
Until 2023, geographic atrophy had no approved treatment. In February that year the FDA approved pegcetacoplan (Syfovre), and in August it approved avacincaptad pegol (Izervay)4. Both drugs block parts of the complement system, an immune pathway: Syfovre targets a protein called C3 and Izervay targets C54. Both slow the disease, but neither stops it, Tech Times notes1.
Eye specialists welcomed those approvals but also pointed out their limits. Speaking to HCPLive in 2023, retina specialist Carl Danzig said:
But, patients don’t necessarily see the impact as they would with wet AMD. There is not that visual improvement.
Pravin Dugel, then president of Izervay’s developer Iveric Bio, raised another question about the complement approach: “are we treating too late?”4.
OliX is betting on a different route. Tech Times describes complement and the MyD88 pathway as parallel and largely separate inflammatory routes to the same loss of retinal cells, and notes that Syfovre and Izervay do not act on MyD881. That is a description of the biology based mostly on lab and animal work. Whether switching off MyD88 helps people, alone or alongside existing drugs, has not been tested.
The drug’s design is also part of OliX’s pitch. Its version of the gene-silencing molecule is built with one strand shorter than the other, which the company says reduces unwanted effects on other genes and lets the molecule enter cells without being wrapped in tiny fat bubbles (lipid nanoparticles)1. That matters for injections into the eye, where such fat-bubble carriers can cause inflammation1. The underlying technique, RNA interference, earned Andrew Fire and Craig Mello the 2006 Nobel Prize in Physiology or Medicine1.
What to watch next
- Whether the FDA lets the 30-day window pass without a hold, allowing US enrollment to begin1.
- Whether OliX resubmits in New Zealand and wins approval there, and how its Australian application proceeds2.
- When the 64-person trial reports, and whether any change on eye scans comes with changes in how well patients see1.
- Whether the earlier safety results are published in full, with the number of patients and doses tested.
